The Tyrosine Kinase Inhibitor ZD 1839 ( “ Iressa ” ) Inhibits HER 2-driven Signaling and Suppresses the Growth of HER 2-overexpressing Tumor Cells 1

@inproceedings{Moasser2001TheTK,
  title={The Tyrosine Kinase Inhibitor ZD 1839 ( “ Iressa ” ) Inhibits HER 2-driven Signaling and Suppresses the Growth of HER 2-overexpressing Tumor Cells 1},
  author={Mark M. Moasser and Andrea Basso and Steven D. Averbuch and Neal Rosen},
  year={2001}
}
The epidermal growth factor receptor (EGFR) is commonly overexpressed in many human tumors and provides a new target for anticancer drug development. ZD1839 (“Iressa”), a quinazoline tyrosine kinase inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials. However, because it remains unclear which tumor types are the best targets for treatment with this agent, the molecular characteristics that correlate with tumor sensitivity to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 72 extracted citations

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTKI), shows evidence of good tolerability and activity: final results from a Phase I study

D. Ferry, L. Hammond, +7 authors E. Rowinsky
Proc. Am. Soc. Clin. Oncol., • 2000

Overall survival advantage to simultaneous chemotherapy plus the humanized anti-Her2 monoclonal antibody Herceptin in Her2-overexpressing metastatic breast cancer

L. Norton, D. J. Slamon, +8 authors S. Shak
Proc. Amer. Soc. Clin. Oncol., • 1999

Phase I study of oral ZD1839, a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): evidence of good tolerability and activity

M. G. Kris, M. Ranson, +4 authors E. Rowinsky
Clin. Cancer Res., • 1999

Similar Papers

Loading similar papers…